Novo Nordisk news

The €2.1 billion investment will double the Chartres site's capacity, add new production processes, and create over 500 jobs by 2028, enhancing Novo Nordisk's ability to meet future medicine demands.

The €5.6 billion investment will expand API and packaging capacity, create 800 jobs, and enhance sustainability. Completion is expected between 2025-2029, with 3,000 external workers during construction.

The €2.1bn investment will expand API production in Hillerød, creating 340 jobs by 2029. The facility will enhance production capacity, flexibility, and sustainability for future chronic disease treatments.

A new biogas plant in Kalundborg will convert 300,000 tonnes of biomass annually, reducing CO2 by 17,000 tonnes and creating 15-20 jobs. The plant will be operational by spring 2018.

The new plant in Bagsværd will boost capacity for diabetes drug development, create 35 jobs, and be operational by late 2016. It features one purification line with potential for expansion.